       Document 0652
 DOCN  M9620652
 TI    Pharmacokinetics of fluconazole after oral administration in children
       with human immunodeficiency virus infection.
 DT    9602
 AU    Nahata MC; Brady MT; College of Pharmacy, Ohio State University, Wexner
       Institute for; Pediatric Research, Children's Hospital, Columbus 43210,
       USA.
 SO    Eur J Clin Pharmacol. 1995;48(3-4):291-3. Unique Identifier : AIDSLINE
       MED/96037144
 AB    The objective of this study was to determine the pharmacokinetics of
       fluconazole after oral administration in children with human
       immunodeficiency virus (HIV) infection. After an overnight fast, a
       single dose of either 2 mg.kg-1 or 8 mg.kg-1 was administered in a
       suspension; five children received 2 mg.kg-1 and four 8 mg.kg-1 (ages
       5-13 years). Blood samples were collected at various times on day 1, and
       once daily on days 2-7 after the dose. Fluconazole serum concentrations
       were measured by gas chromatography. At the dose of 2 mg.kg-1, the Cmax,
       AUC (0-infinity), and t1/2 ranged from 2.3-4.4 micrograms.ml-1, 84.9-136
       micrograms.h.ml-1, and 19.8-34.8 h, respectively. At the dose of 8
       mg.kg-1 the Cmax, AUC (0-infinity), and t1/2 ranged from 5.4-12.1
       micrograms.ml-1, 330-684 micrograms h.ml-1, and 25.6-42.3 h,
       respectively. When compared with published data in healthy adults,
       fluconazole achieved similar serum concentrations in the present group
       of children, indicating a nearly complete degree of absorption.
 DE    *Administration, Oral  Adolescence  Child  Female
       Fluconazole/*PHARMACOKINETICS  Human  HIV  Male  Pharmacokinetics
       Support, Non-U.S. Gov't  Time Factors  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

